Curis
Highly Engaged Employees
Highly Engaged EmployeesChemicals & Related Products · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
128 Spring St Ste 500 Bldg C, Lexington,...Phone Number
(617) 503-6500Website
www.curis.comRevenue
$7.1 MillionStock Symbol
CRISIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Curis
Curis, Inc. is a biotechnology company headquartered in Lexington, Massachusetts, focused on discovering, developing, and commercializing innovative cancer therapeutics. Its clinical-stage pipeline includes emavusertib, an oral IRAK4 kinase inhibitor being studied for relapsed or refractory hematologic malignancies, and fimepinostat, a dual HDAC and PI3K inhibitor for diffuse large B-cell lymphoma. Curis also collaborates with Aurigene Discovery Technologies on immuno-oncology and precision oncology programs and has previously partnered with Genentech and Roche on cancer therapeutics.Explore more
Curis Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Curis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Curis
Website visits: Recent activity has been detected on your website
Curis, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Curis recently announced quarterly report
Product Launch: Get notified when Curis launches new products
Check if Curis has recently received funding, and reach out quickly before it becomes old news!
Click to see if Curis had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Curis has new funding data
Check out if Curis is spiking on competitors!
Recommended Actions
Find VP level buyers at Curis
Find 3 more new buyers
Compare Similar Companies to Curis
Compare insights from companies similar to Curis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Curis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Curis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Curis.
Curis financials insights
Gather financial insights about Curis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Corporate Investment
$8M
2012
Debt
$30M
2015
Stock Offering
$64.7M
2020
Share Placement
$30M
Debt
$350K
2026
Private Equity
$20.2M
Curis Tech Stack
A closer look at the technologies used by Curis
Most Recent Scoops
Project
Curis has reported an overall response rate (ORR) of 86% in BTKI-naive patients enrolled in the Take Aim Lymphoma Study as of the July 1, 2026 data cutoff, with 6 of 7 patients achieving a response, up from 71% reported at the May 1, 2025 data cutoff. Among evaluable patients who completed at least one cycle of treatment, the response rate increased to 100% (5 of 5 patients), compared to published BTK inhibitor monotherapy studies in PCNSL that have generally shown response rates of 40% to 70%.
Person-Based
Medical Research
Person-Based
Medical Research
Person-Based
Medical Research
Person-Based
Curis News & Media
Curis Doses First Five Patients in TakeAim CLL Study
LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study...Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript
Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma July 22, 2026 8:30 AM EDTCompany ParticipantsDiantha...Curis Announces Positive Emavusertib Update
Updated Clinical Data in PCNSL Increased Guidance on Year-End Data in CLL Company to Host Webcast at 8:30 a.m. ET LEXINGTON, Mass., July 22, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available,...Curis Consents First Six Patients in TakeAim CLL Study
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study....
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Curis
Sign Up For FreeTo access detailed company insights
Curis, Inc. is a biotechnology company headquartered in Lexington, Massachusetts, focused on discovering, developing, and commercializing innovative cancer therapeutics. Its clinical-stage pipeline includes emavusertib, an oral IRAK4 kinase inhibitor being studied for relapsed or refractory hematologic malignancies, and fimepinostat, a dual HDAC an... Read More
